AUTHORS
Jonathan Isenberg, MD, Alina S. Gerrie, MD, FRCPC, MPH2, Kerry Savage, MD, MSc, BSc3, Andrew Cowan, MD4, David Scott, MD5, Laurie H. Sehn, MD6, Diego Villa, MD7, Jesse Shustik, MD8, Ashley Freeman, MD9, Kevin Song, MD10, Florian Kuchenbauer11, Stephen Parkin, MD12, Julia Varghese, MD13, Elaine Fung, N/A14, Anna Nguyen15, Christopher P. Venner, MD16
AFFILIATIONS
1 Division of Medical Oncology, University of British Columbia and Centre for Lymphoid Cancer, BC Cancer, VANCOUVER, British Columbia, Canada
2 Division of Medical Oncology, University of British Columbia and Centre for Lymphoid Cancer, BC Cancer, VANCOUVER, British Columbia, Canada
3 Division of Medical Oncology, University of British Columbia and Centre for Lymphoid Cancer, BC Cancer, VANCOUVER, British Columbia, Canada
4 Division of Medical Oncology, University of British Columbia and Centre for Lymphoid Cancer, BC Cancer, VANCOUVER, British Columbia, Canada
5 Division of Medical Oncology, University of British Columbia and Centre for Lymphoid Cancer, BC Cancer, VANCOUVER, British Columbia, Canada
6 Division of Medical Oncology, University of British Columbia and Centre for Lymphoid Cancer, BC Cancer, VANCOUVER, British Columbia, Canada
7 Division of Medical Oncology, University of British Columbia and Centre for Lymphoid Cancer, BC Cancer, VANCOUVER, British Columbia, Canada
8 Division of Medical Oncology, University of British Columbia and Centre for Lymphoid Cancer, BC Cancer, Surrey, British Columbia, Canada
9 Division of Medical Oncology, University of British Columbia and Centre for Lymphoid Cancer, BC Cancer, Victoria, British Columbia, Canada
10 VGH, VANCOUVER, British Columbia, Canada
11 VGH, VANCOUVER, British Columbia, Canada
12 VGH, VANCOUVER, British Columbia, Canada
13 VGH, VANCOUVER, British Columbia, Canada
14 Division of Medical Oncology, University of British Columbia and Centre for Lymphoid Cancer, BC Cancer, VANCOUVER, British Columbia, Canada
15 Division of Medical Oncology, University of British Columbia and Centre for Lymphoid Cancer, BC Cancer, VANCOUVER, British Columbia, Canada
16 Division of Medical Oncology, University of British Columbia and Centre for Lymphoid Cancer, BC Cancer, VANCOUVER, British Columbia, Canada
ABSTRACT
Background:
Anti-CD38–based regimens combined with lenalidomide and/or bortezomib plus dexamethasone are standard frontline therapy for newly diagnosed, transplant ineligible multiple myeloma (TI-NDMM). However, Daratumumab, lenalidomide, and dexamethasone (DRd) remains a standard regimen in many jurisdictions. As anti-CD38–based quadruplets are increasingly adopted, real-world outcomes with DRd provide an important benchmark. In addition, patients (pts) aged >80 years were underrepresented or excluded from pivotal frontline trials. We evaluated frontline DRd in a population-based cohort in British Columbia (BC), focusing on early progression and post-progression outcomes.
Methods:
We performed a retrospective population-based study of all consecutive pts with NDMM treated with first-line DRd in BC. As DRd became publicly available in January 2022, all pts initiating DRd between January 2022 and April 2026 were identified through provincial pharmacy records and included. Clinical data were obtained from the provincial myeloma database and electronic medical records. Outcomes included overall response rate (ORR), progression-free survival (PFS), overall survival (OS), second PFS (PFS2) defined as time from DRD to 2nd progression, and outcomes after 2nd line treatment (2nd PFS and 2nd OS). Baseline predictors of PFS and OS were evaluated using Cox regression.
Results:
A total of 520 pts were included. Median age was 76 years (range 47–99); 31% were aged >80 years and 10% over >85. All were transplant-ineligible: 93% due to age, comorbidities, or performance status (PS), and 7% by pt or physician preference. ECOG PS ≥2 was present in 34%. High-risk cytogenetics (HRC; del17p, del1p, gain1q, t(4;14), or t(14;16)) were identified in 36%, including double-hit (DH) in 69 pt (13%) and triple-hit (TH) in 13 pt (3%). ORR was 88%, with ≥VGPR in 65%. After a median follow-up of 27.3 months, median PFS (mPFS) was 35.0 months and mOS was not reached (NR). mPFS was NR in pts aged ≤75 years, 35.2 months in those aged 76–80 years, and 24.4 months in those aged >80 years (P=0.086). 152 pts (29%) were functional high risk (FHR18; refractory disease, progression, or death within 18 months), including 6o (39%) pts with standard-risk cytogenetics. mPFS differed significantly by cytogenetic risk (P<0.001), ranging from NR in standard-risk disease to 6.5 months in TH disease. On multivariable analysis, ECOG PS ≥2 (HR 2.62, P<0.001), HRC (HR 1.76, P=0.001), and extramedullary disease (HR 2.15, P=0.016) independently predicted inferior PFS. Overall, 209 pts (40%) progressed on front line DRd, of which 146 (28%) died. For the entire cohort mPFS2 was NR, with 12-, 24-, and 36-month PFS2 rates of 84%, 72%, and 58%, respectively. Eighty-two pts received second-line therapy, predominantly proteasome inhibitor–based. Median 2nd PFS and OS from initiation of 2nd line were 11 and 25.5 months, respectively. In FHR18 pts, median 2nd PFS was 8.6 versus 13.3 months in non FHR18 pts(P=0.10) and median 2nd OS was 15.1 months versus NR, resectively (P=0.08). On multivariable logistic regression, ECOG PS ≥2 (OR 7.79, p<0.001), HRC (OR 1.87, p=0.016), lower plt count (OR 0.82 per 50 ×10⁹/L increase, p=0.011) and lower albumin (OR 0.83 per 5 g/L increase, p=0.048) were independently associated with FHR18. Lenalidomide and dexamethasone dose modifications occurred in 85% of evaluable pts, while daratumumab or lenalidomide discontinuation due to toxicity or intolerance occurred in 21%. Grade ≥3 infections occurred in 19%, VTE in 7%, and lenalidomide-associated rash in 8%.
Conclusions:
Frontline DRd achieved high ORR in NDMM, including very elderly pts underrepresented in clinical trials. Although mPFS was shorter in pts aged >80 years, age was not independently associated with inferior PFS. Our finding of a mPFS of 35 months, compared with the pivotal MAIA trial showing mPFS of 61.9 months for front line DRd, underscores the importance of real-world analyses in evaluating treatment effectiveness outside the clinical trial setting. Nearly one-third of the pts in our cohort met criteria for FHR18, including 39% with standard-risk cytogenetics, highlighting limitations of cytogenetic risk stratification alone. Poor post-progression outcomes in FHR18 underscore the need for improved salvage strategies in this population
DISCLOSURES
Jonathan Isenberg, MD: No relevant conflicts of interest to declare.